See what happened at SABCS 2023  Learn more
ODX image

Turn what if
into what is.

The Oncotype DX Breast Recurrence Score® test provides personalized genomic insights for early-stage HR+, HER2- breast cancer patients.

The only test proven to predict likelihood of chemotherapy benefit1,2

  • Provides a Recurrence Score® result, which assesses the expression of 21 genes—16 cancer-related genes and 5 reference genes—in a tumor sample using reverse transcription polymerase chain reaction (RT-PCR)3
  • Comprehensive genomic assessment also includes risk of distant recurrence with endocrine therapy alone4
  • Predicts the benefit of adding chemotherapy to endocrine therapy1,2
  • Provides a quantitative estrogen receptor (ER) score to help assess the magnitude of hormonal therapy benefit, along with additional supporting information such as progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) scores3

Gain insight into specific tumor biology, risk assessment, and magnitude of chemotherapy benefit to help inform what’s best for your patient.

Included in all major breast cancer treatment guidelines

The 21-gene assay (Oncotype DX®) test is included in leading oncology guidelines,
such as those from the  National Comprehensive Cancer Network® (NCCN®).5*

*National Comprehensive Cancer Network and NCCN are registered trademarks of the National Comprehensive Cancer Network.


Treat with even more confidence

All genomic tests are not created equal

Compare to other tests

TAILORx provides definitive answers for node-negative patients

The 12-year results of the Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx) identified 85% of women with early-stage, node-negative breast cancer who may receive no benefit from chemotherapy, and 15% for whom chemotherapy can be
life-saving. 4,6,7

Read the groundbreaking results

RxPONDER provides definitive answers for node-positive patients

The RxPONDER trial (A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer) showed that most women with 1-3 positive nodes and Recurrence Score results of 0-25 can safely forgo chemotherapy. It builds on data from SWOG-8814 that established prediction of chemotherapy benefit for patients with Recurrence Score results of 26-100.2,8-11

More on RxPonder

Coverage and financial assistance

The Exact Sciences Genomic Access Program is committed to helping patients access the Oncotype DX test.

View coverage details

Interactive Report
Guide

Dive into the Interactive Report Guide
and learn how to interpret results for
your patient.

Explore the report

Icon box

Order a test

We make your ordering experience efficient. You can order tests through the physician portal, and we’ll help you every step of the way.

See how to order